Clinical trial · Observational
Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer
NCT01767974CI-TRIAL-00008896SPACEunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be performed. The detection rates of EGFR mutation will be compared using paired samples.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Non-Small Cell Lung Cancer
- description
- Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
Primary outcomes (1)
- measure
- Detection rate of EGFR mutation
- timeFrame
- two weeks
- description
- To prove higher detection rate of EGFR mutation with PNA clamping compared with sequencing
Secondary outcomes (1)
- measure
- Verification of PNA positive casese
- timeFrame
- Two weeks
- description
- To analyze the Sequencing negative/PNA clamping positive group (where sample is available) with another sensitive technique COBAS test
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Locally advanced stage IIIB not suitable for curative therapy or stage IV (metastatic) disease or relapsed NSCLC * ECOG Performance status 0\~2. * Written Informed Consent * Female or male patients aged 18 years or over, eligible for treatment for NSCLC Exclusion Criteria: * Previous exposure to EGFR-TKI * Concomitant use of other anti-cancer drugs with EGFR-TKI * Patients without available Tumor DNA * As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) * Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study * Pregnancy or breast-feeding women (women of child¬bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy.
References
Publications (0)
Data not yet available
No reference posted for this study.